TrialClinical pharmacology and therapeutics2022

Exposure-Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies.

Arnab Mukherjee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.